Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

STEP Pharm II > Drugs for Restrictive Lung Diseases and Pulmonary Artery Hypertension > Flashcards

Drugs for Restrictive Lung Diseases and Pulmonary Artery Hypertension Flashcards

1
Q

Silicosis is a disease typically seen in what patient population?

A

sand blasters, rock miners, and stone cutters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Berylliosis is a disease typically seen in what patient population?

A

workers of aerospace, nuclear weapon, and electronic industries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Silicosis places a patient at increased risk of what?

A

TB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Coal worker’s pneumoconiosis places a patient at increased risk of what?

A

-right sided heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Asbestosis places a patient at increased risk of what?

A

-malignant mesothelioma-carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Excessive doses of what drugs have been known to precipitate ARDS?

A

-aspirin-cocaine-tricyclic antidepressants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What other thing increases the risk of ARDS?

A

alcohol abuse (only increases risk of trauma and sepsis, doesn’t actually cause it)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some potential durgs for the treatment of ARDS?

A

-B2 agonist-NO-PGI2 Inhaled-Corticosteroids-Dietary oil supplements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is neonatal respiratory distress syndrome treated?

A

-antenatal corticosteroids (increase release of surfactant)-exogenous surfactant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When is exogenous surfactant administered in patients at risk of NRDS?

A

pre-30 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What products are naturally rich in surfactant proteins B and C and DPPC?

A

-Poractant alfa-Calfactant-Beractant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the hallmark of sarcoidosis?

A

young black female with non-caseating granulomas involving MULTIPLE organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment for sarcoidosis?

A

-glucocorticoids-methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How doe glucocorticoids work?

A

they act principally by binding to glucocorticoidreceptors and modulatingtranscriptional regulation in the nucleus and thus inhibiting pro-inflammatory cytokine production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What cytokines do glucocorticoids inhibit?

A

-IL-1B-TNF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What cytokines do glucocorticoids PROMOTE?

A

IL-10 by macrophages and dendritic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are some AEs of chronic glucocorticoid use?

A

osteoporosis,pancreatitis, steroid-induced diabetes mellitus, cataracts, glaucoma, psychosis, immunosuppression, weight gain, and skinatrophy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What infections are particularly common in those chronically taking glucocorticoids?

A

candidiasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How does Methotrexate work?

A

DHFR (dihydrofolate reductase) inhibitionand increases adenosine-mediated immunosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How does Methotrexate increase adenosine-mediated immunosuppression?

A

inhibits conversion of GAR to FGAR and AICAR to FAICAR (stronger)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What does accumulated AICAR result in?

A

AMP deaminase and adenosine deaminase (ADA) activity with increased adenosine 5-P and adenosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What does accumulation of adenosine 5-P and adenosine in the cell cause?

A

more EXTRAcellular adenosine 5-P and adenosine which binds to A2 receptors yielding an increase cAMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What does increase in cAMP cause?

A

this is the DIRECT cause of immunosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

T or F. Methotrexate is NOT front-line therapy for its anti-inflammatoryeffects.

A

T.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

AEs of methotrexate?

A

-dermatologic rxns-birth defects-malignant lymphoma -pulmonary fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Is idiopathic pulmonary fibrosis a chronic inflammatory disease?

A

No (even the most potent anti-inflammatory agents don’t help)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What happens in IPF?

A

The altered mesenchymal cell phenotype and blockade of apoptosis give rise to an altered stromal cell population and the activated epithelium release a series of profibrogenic factors, TGF-b and PDGF. This creates a new microenvironment in patchy areas (Other areas remain normal instructure and environment.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Why is pulmonary HTN (greater than 25 mmHg) seen in IPF?

A

remodeling of vessels can occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Drugs for IPF?

A

pirfenidone [Esbriet] and Nintedanib [Ofev].

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What does Nintedanib do?

A

a TKI of VEGF, fibroblast growth factor receptor and PDGF receptormore effective of the two at reducing exacerbations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

MOA of Piferidone?

A

Unknown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is Goodpasture’s syndrome?

A

type II hypersensitivity against the a3 chain of type IV collagen in the BM of lungs and kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

How is GP treated?

A

plasmapheresis

34
Q

What is Wegener’s Granulomatosis?

A

This is an ANCA-positive autoimmune vasculitis (small-medium vessels), primarily of theupper respiratory tract, lungs and kidney.

35
Q

Treatment of Wegener’s Granulomatosis?

A

-Rituximab -Azathioprine-Cyclophosphamide-Steroids

36
Q

How does Rituximab work?

A

a monoclonal antibody that binds the CD20 cell surface antigen on B-cell precursors and mature B-lymphocytes.

37
Q

How does Rituximab promote cell death?

A

1) AB-dependent recruitment of NK and macrophages2) Complement activation3) Apoptosis induction

38
Q

AEs of Rituximab?

A

-HTN-pruritis/urticaria-asthenia and arthralgia

39
Q

How does Azathioprine work?

A

DNA and RNA synthesis inhibitor that also produces immunosuppression,possibly by facilitating apoptosis of T cell populations.

40
Q

AEs of Azathioprine?

A

-leukopenia/thrombocytopenia-neoplasms

41
Q

How does Cyclophosphamide work?

A

an alkylating agent that also produces (B & T cell) lymphopenia, selective suppression of B-lymphocyte activity and decreased immunoglobulin secretion.

42
Q

AEs of Cyclophosphamide?

A

-bladder cancer-myeloproliferative malignancy-neutropenia

43
Q

Pulmonary HTN can occur from what four min mechanisms?

A

1) an imbalance betweenvasoconstriction and vasodilation (due to a relative decrease in prostacyclin and NOproduction, as well as an increased production of endothelin-1 and a more pronounced presence ofthromboxane A2); 2) smooth muscle and endothelial cell proliferation, propagation, and hypertrophy (dueto the production of growth inhibitors and mitogenic factors); 3) thrombosis; and 4) fibrosis.

44
Q

What are Plexiformlesions?

A

Thickened arterioles as a result of shear stress- are the histologic hallmark of patients with IPAH or heritable PAH. These lesions result in proliferation of monoclonal endothelial cells, smoothmuscle cells, and an accumulation of circulating cells (e.g., macrophages and progenitor cells) andlead to significant obstruction of blood flow.

45
Q

The approach to pulmonary HTN therapy is based on what?

A

severity of disease

46
Q

What are some drug options for pulmonary HTN?

A

-Prostanoids-Endothelin-1 receptor antagonists -Phosphodiesterase Type 5 Inhibitors -CCBs

47
Q

What are some prostanoids?

A

-Epoprostenol-Iloprost-Treprostinil

48
Q

How do Prostanoids work?

A

Induce pulmonary artery vasodilation, retard smooth muscle growth and disrupt platelet aggregation

49
Q

How is Epoprostenol given?

A

continuous IV (T1/2= 3-5 min)

50
Q

AEs of Epoprostenol?

A

-hypotension-risk of catheter infection

51
Q

How is Iloprost given?

A

6-9 inhaled doses/day (T1/2= 25 min)

52
Q

AEs of Iloprost?

A

-hemoptysis -cough, flushing, and headaches

53
Q

How is Treprostinil given?

A

continuous SC or IV infusion (T1/2=4 hrs)

54
Q

AEs of Treprostinil?

A

-injection site rxn-jaw pain-diarrhea

55
Q

DD interactions of Treprostinil?

A

CYP2C8 drugs (gemfibrozil and rifampin)

56
Q

What is something to always monitor when giving prostanoids?

A

bleeding risk

57
Q

T or F. Endothelin-1 Receptors antagonists are available PO

A

T. Advantage over Prostanoids

58
Q

What are the Endothelin-1 Receptors antagonists?

A

-Bosentan-Ambrisentan

59
Q

How is Bosentan given?

A

PO BID

60
Q

AEs of Bosentan?

A

-liver damage-anemia-CYP inducer -nasopharyngitis

61
Q

How is Ambrisentan given?

A

PO QD

62
Q

AEs of Ambrisentan?

A

-peripheral edema -headache-CYP2C9, 3A4 metabolism

63
Q

Which Endothelin-1 Receptor antagonist is tetraogenic?

A

Both

64
Q

How do Phosphodiesterase Type 5 Inhibitors work?

A

perpetuate endogenously generated cGMP leading to vasodilation and reduce cellular proliferation.

65
Q

Phosphodiesterase Type 5 Inhibitors should never been taken in which patients?

A

those taking organic nitrates

66
Q

What are the Phosphodiesterase Type 5 Inhibitors?

A

-Sildenafil-Tadalafil

67
Q

AEs of Sildenafil?

A

-headache-nosebleed-dizziness with sudden hearing loss -CYP

68
Q

AEs of Tadalafil?

A

-headache-change in color vision-CYP -back pain

69
Q

How do CCBs work?

A

preventing access of Ca2+ into cells duringmembrane depolarization, thus blocking the key mediator of smooth muscle contraction

70
Q

Are CCBs effective in pulmonary HTN?

A

some, but not all patients will benefit (some may undergo a vasodilator challenge before use)

71
Q

What are some drugs used for vasodilatory challenge of pulmonary circulation?

A

-IV epoprostenol-adenosine-inhaled NO

72
Q

How does a vasodilatory challenge work?

A

Patients receive a carefully escalated dosing rate and pulmonary arterial pressure (PAP) and cardiac output (CO) are monitored for 2-3 hr. Apatient who responds positively to a vasodilator challenge (i.e., lower PAP without lower CO) maythen be prescribed certain CCBs

73
Q

Why even worry about doing a vasodilatory challenge?

A

limit risk of potentially fatal hemodynamic decompensation with CCBs

74
Q

What are some CCBs?

A

-Diltiazem-Nifedipine-Amlodipine

75
Q

How are CCBs given?

A

PO

76
Q

AEs of Diltiazem?

A

-bradycardia, hypotension-edema

77
Q

AEs of Nifedipine?

A

-flushing, edema-heartburn

78
Q

AEs of Amlodipine?

A

-edema-fatigue-hypotension

79
Q

Something to always consider with CCBs?

A

CYP substrate

80
Q

Why is Verapamil avoided with PAH treatment?

A

Because of its strong negative inotropic properties, whichmakes it more likely to induce symptomatic bradycardia than the others.

81
Q

What is the goal of CCB treatment?

A

Is for the patient to achieve NYHA-FC I or IIafter 3–4 months. If this is not achieved, alternative therapy needs to be considered.

82
Q

Define NYHA-FC I or II

A

I) No limitations or symptoms associatedwith normal physical activityII) Mild symptoms and/or slight limitationduring normal physical activity

STEP Pharm II (42 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions